Literature DB >> 32119845

The frontiers of addressing antibiotic resistance in Neisseria gonorrhoeae.

Daniel H F Rubin1, Jonathan D C Ross2, Yonatan H Grad3.   

Abstract

The sexually transmitted infection gonorrhea, caused by the Gram-negative bacterium Neisseria gonorrhoeae, can cause urethritis, cervicitis, and systemic disease, among other manifestations. N. gonorrhoeae has rapidly rising incidence along with increasing levels of antibiotic resistance to a broad range of drugs including first-line treatments. The rise in resistance has led to fears of untreatable gonorrhea causing substantial disease globally. In this review, we will describe multiple approaches being undertaken to slow and control this spread of resistance. First, a number of old drugs have been repurposed and new drugs are being developed with activity against Neisseria gonorrhoeae. Second, vaccine development, long an important goal, is advancing. Third, new diagnostics promise rapid detection of antibiotic resistance and a shift from empiric to tailored treatment. The deployment of these new tools for addressing the challenge of antibiotic resistance will require careful consideration to provide optimal care for all patients while extending the lifespan of treatment regimens.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32119845      PMCID: PMC7293957          DOI: 10.1016/j.trsl.2020.02.002

Source DB:  PubMed          Journal:  Transl Res        ISSN: 1878-1810            Impact factor:   7.012


  155 in total

1.  Type IIA topoisomerase inhibition by a new class of antibacterial agents.

Authors:  Benjamin D Bax; Pan F Chan; Drake S Eggleston; Andrew Fosberry; Daniel R Gentry; Fabrice Gorrec; Ilaria Giordano; Michael M Hann; Alan Hennessy; Martin Hibbs; Jianzhong Huang; Emma Jones; Jo Jones; Kristin Koretke Brown; Ceri J Lewis; Earl W May; Martin R Saunders; Onkar Singh; Claus E Spitzfaden; Carol Shen; Anthony Shillings; Andrew J Theobald; Alexandre Wohlkonig; Neil D Pearson; Michael N Gwynn
Journal:  Nature       Date:  2010-08-04       Impact factor: 49.962

2.  New treatment options for Neisseria gonorrhoeae in the era of emerging antimicrobial resistance.

Authors:  David A Lewis
Journal:  Sex Health       Date:  2019-09       Impact factor: 2.706

3.  Penicillinase-producing Neisseria gonorrhoeae.

Authors:  W A Ashford; R G Golash; V G Hemming
Journal:  Lancet       Date:  1976-09-25       Impact factor: 79.321

4.  Susceptibility of Neisseria gonorrhoeae to Gentamicin-Gonococcal Isolate Surveillance Project, 2015-2016.

Authors:  Laura M Mann; Robert D Kirkcaldy; John R Papp; Elizabeth A Torrone
Journal:  Sex Transm Dis       Date:  2018-02       Impact factor: 2.830

5.  In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria.

Authors:  Michael D Huband; Patricia A Bradford; Linda G Otterson; Gregory S Basarab; Amy C Kutschke; Robert A Giacobbe; Sara A Patey; Richard A Alm; Michele R Johnstone; Marie E Potter; Paul F Miller; John P Mueller
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.191

6.  Gonorrhea and the beginnings of clinical research ethics.

Authors:  Thomas G Benedek
Journal:  Perspect Biol Med       Date:  2005       Impact factor: 1.416

7.  Impact of an Immunization Campaign to Control an Increased Incidence of Serogroup B Meningococcal Disease in One Region of Quebec, Canada.

Authors:  Philippe De Wals; Geneviève Deceuninck; Brigitte Lefebvre; Raymond Tsang; Dennis Law; Gaston De Serres; Vladimir Gilca; Rodica Gilca; Nicole Boulianne
Journal:  Clin Infect Dis       Date:  2017-05-01       Impact factor: 9.079

8.  Solithromycin inhibition of protein synthesis and ribosome biogenesis in Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae.

Authors:  Ward Rodgers; Ashley D Frazier; W Scott Champney
Journal:  Antimicrob Agents Chemother       Date:  2013-01-14       Impact factor: 5.191

9.  Global challenges of implementing human papillomavirus vaccines.

Authors:  Janice E Graham; Amrita Mishra
Journal:  Int J Equity Health       Date:  2011-06-30

10.  Azithromycin Resistance and Decreased Ceftriaxone Susceptibility in Neisseria gonorrhoeae, Hawaii, USA.

Authors:  John R Papp; A Jeanine Abrams; Evelyn Nash; Alan R Katz; Robert D Kirkcaldy; Norman P O'Connor; Pamela S O'Brien; Derek H Harauchi; Eloisa V Maningas; Olusegun O Soge; Ellen N Kersh; Alan Komeya; Juval E Tomas; Glenn M Wasserman; Gail Y Kunimoto; David L Trees; A Christian Whelen
Journal:  Emerg Infect Dis       Date:  2017-05       Impact factor: 6.883

View more
  4 in total

Review 1.  Collateral Damage: A Narrative Review on Epidemics of Substance Use Disorders and Their Relationships to Sexually Transmitted Infections in the United States.

Authors:  Steffanie Ann Strathdee; Claire C Bristow; Tommi Gaines; Steven Shoptaw
Journal:  Sex Transm Dis       Date:  2021-07-01       Impact factor: 3.868

Review 2.  Bridging the gap between development of point-of-care nucleic acid testing and patient care for sexually transmitted infections.

Authors:  Kuangwen Hsieh; Johan H Melendez; Charlotte A Gaydos; Tza-Huei Wang
Journal:  Lab Chip       Date:  2022-02-01       Impact factor: 7.517

Review 3.  Tissue Models for Neisseria gonorrhoeae Research-From 2D to 3D.

Authors:  Motaharehsadat Heydarian; Eva Rühl; Ravisha Rawal; Vera Kozjak-Pavlovic
Journal:  Front Cell Infect Microbiol       Date:  2022-02-11       Impact factor: 5.293

4.  Molecular characterization of a ceftriaxone-resistant Neisseria gonorrhoeae strain found in Switzerland: a case report.

Authors:  Konrad Egli; Anna Roditscheff; Ursula Flückiger; Martin Risch; Lorenz Risch; Thomas Bodmer
Journal:  Ann Clin Microbiol Antimicrob       Date:  2021-08-06       Impact factor: 3.944

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.